Registration for a live webinar on 'Chronic inflammation, immune cell trafficking and anti-trafficking agents' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this free, full length talk
Topics Covered
- Diversity and incidence of neurological symptoms attributable to COVID-19
- Mechanisms by which SARS-CoV-2 infection triggers neurological symptoms
- Singularity of SARS-CoV-2, among coronaviruses, in triggering neurological symptoms
- Therapeutic approaches to prevent or improve neurological symptoms
- Incidence of psychiatric symptoms resulting from COVID-19 in a subset of patients
- Relationship between neurological and psychiatric symptoms
Biography
Michael Zandi is a consultant neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London, and honorary associate professor at the UCL Queen Square Institute of Neurology. He trained in medicine at Cambridge and his work has centred on autoimmune encephalitis. He co-chairs the encephalitis meeting at the UCL Queen Square and UCLH National Hospital for Neurology and Neurosurgery since 2017, and weekly Covid-19 neurology meeting there since April 2020. He and his colleagues are working on the neurological and psychiatric complications of Covid-19, T cell biology of autoimmune encephalitis with MRC support, neuroimmunology of catatonia with Wellcome Trust support, and biomarkers of neuroimmunological disorders.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Zandi, M. (2020, October 27). The neurological symptoms of COVID-19 [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 6, 2023, from https://hstalks.com/bs/4448/.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Michael Zandi has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Interviews on Covid-19
Transcript
0:00
Interviewer: Dr. Michael Zandi, thank you very much for taking
the time to do this interview with us today to discuss
the collection of neurological symptoms reported to date
with regards to patients having suffered from COVID-19.
First of all, can you provide an account of the breadth of neurological symptoms
and events that you have now documented as potential COVID-19 symptoms,
and what is their prevalence in COVID patients?
Dr. Zandi: Thanks very much and thanks, Scott,
for inviting me and it's a pleasure to
speak to you today and take part in this interview.
We've known since COVID-19 was first described,
the first reports in China from Wuhan that neurological symptoms are quite common,
at least in hospitalized patients.
Perhaps up to a third of people who have been
hospitalized with COVID have had neurological symptoms of some kind,
but it's less clear really what represents disease in the brain or in the nerves.
We know, for example,
that it may be a quarter or a third of people who are in
hospital with COVID and often requiring oxygen.
This is relatively severe disease compared to those who don't come into hospital.
But those who do come into hospital,
around a third or a quarter can be confused,
have a delirium, have memory problems,
and that can be short-lived and get better over a few days.
But we have seen this occur in people a week or after their original respiratory illness.
We really don't know what the incidence prevalence is
on a larger scale because we're all learning about this illness,